Alnylam Pharmaceuticals, Inc. (ALNY)

$244.89

-1.91

(-0.77%)▲

Market is closed - opens 8 PM, 25 Nov 2024

Performance

  • $243.74
    $248.75
    $244.89
    downward going graph

    0.47%

    Downside

    Day's Volatility :2.02%

    Upside

    1.55%

    downward going graph
  • $141.98
    $304.39
    $244.89
    downward going graph

    42.02%

    Downside

    52 Weeks Volatility :53.36%

    Upside

    19.55%

    downward going graph

Returns

PeriodAlnylam Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-10.18%
-7.3%
0.0%
6 Months
63.94%
-0.5%
0.0%
1 Year
50.31%
10.5%
0.0%
3 Years
30.85%
8.8%
-24.0%

Highlights

Market Capitalization
31.8B
Book Value
$0.25
Earnings Per Share (EPS)
-2.62
PEG Ratio
-0.49
Wall Street Target Price
301.215
Profit Margin
-15.86%
Operating Margin TTM
-15.35%
Return On Assets TTM
-2.92%
Return On Equity TTM
-1500.66%
Revenue TTM
2.1B
Revenue Per Share TTM
16.52
Quarterly Revenue Growth YOY
-33.300000000000004%
Gross Profit TTM
868.6M
EBITDA
-132.1M
Diluted Eps TTM
-2.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.17
EPS Estimate Next Year
0.44
EPS Estimate Current Quarter
-0.93
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    70%Buy
    29%Hold
    0
    0%Sell
Based on 34 Wall street analysts offering stock ratings for Alnylam Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 34 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
24
25
Hold
10
10
8
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 23.0%

Current $244.89
Target $301.21

Company Financials

FY18Y/Y Change
Revenue
74.9M
↓ 16.69%
Net Income
-761.5M
↑ 55.13%
Net Profit Margin
-1.0K%
↓ 470.63%
FY19Y/Y Change
Revenue
219.8M
↑ 193.36%
Net Income
-886.1M
↑ 16.37%
Net Profit Margin
-403.24%
↑ 613.34%
FY20Y/Y Change
Revenue
492.9M
↑ 124.28%
Net Income
-858.3M
↓ 3.14%
Net Profit Margin
-174.15%
↑ 229.09%
FY21Y/Y Change
Revenue
844.3M
↑ 71.31%
Net Income
-852.8M
↓ 0.64%
Net Profit Margin
-101.01%
↑ 73.14%
FY22Y/Y Change
Revenue
1.0B
↑ 22.88%
Net Income
-1.1B
↑ 32.64%
Net Profit Margin
-109.04%
↓ 8.03%
FY23Y/Y Change
Revenue
1.8B
↑ 76.23%
Net Income
-440.2M
↓ 61.08%
Net Profit Margin
-24.08%
↑ 84.96%
Q2 FY23Q/Q Change
Revenue
318.8M
↓ 0.17%
Net Income
-276.0M
↑ 58.54%
Net Profit Margin
-86.59%
↓ 32.06%
Q3 FY23Q/Q Change
Revenue
750.5M
↑ 135.46%
Net Income
147.8M
↓ 153.53%
Net Profit Margin
19.69%
↑ 106.28%
Q4 FY23Q/Q Change
Revenue
439.7M
↓ 41.41%
Net Income
-137.9M
↓ 193.31%
Net Profit Margin
-31.35%
↓ 51.04%
Q1 FY24Q/Q Change
Revenue
494.3M
↑ 12.42%
Net Income
-65.9M
↓ 52.18%
Net Profit Margin
-13.34%
↑ 18.01%
Q2 FY24Q/Q Change
Revenue
659.8M
↑ 33.48%
Net Income
-16.9M
↓ 74.39%
Net Profit Margin
-2.56%
↑ 10.78%
Q3 FY24Q/Q Change
Revenue
500.9M
↓ 24.08%
Net Income
-111.6M
↑ 560.61%
Net Profit Margin
-22.27%
↓ 19.71%
FY18Y/Y Change
Total Assets
1.6B
↓ 21.05%
Total Liabilities
272.8M
↑ 19.51%
FY19Y/Y Change
Total Assets
2.4B
↑ 52.09%
Total Liabilities
956.4M
↑ 250.55%
FY20Y/Y Change
Total Assets
3.4B
↑ 42.25%
Total Liabilities
2.4B
↑ 149.97%
FY21Y/Y Change
Total Assets
3.6B
↑ 6.93%
Total Liabilities
3.1B
↑ 27.78%
FY22Y/Y Change
Total Assets
3.5B
↓ 2.66%
Total Liabilities
3.7B
↑ 21.26%
FY23Y/Y Change
Total Assets
3.8B
↑ 7.99%
Total Liabilities
4.1B
↑ 9.34%
Q2 FY23Q/Q Change
Total Assets
3.4B
↑ 0.31%
Total Liabilities
3.8B
↑ 4.36%
Q3 FY23Q/Q Change
Total Assets
3.8B
↑ 12.83%
Total Liabilities
4.0B
↑ 5.1%
Q4 FY23Q/Q Change
Total Assets
3.8B
↓ 0.24%
Total Liabilities
4.1B
↑ 1.14%
Q1 FY24Q/Q Change
Total Assets
3.8B
↓ 0.14%
Total Liabilities
4.0B
↓ 0.17%
Q2 FY24Q/Q Change
Total Assets
4.0B
↑ 4.84%
Total Liabilities
4.0B
↓ 0.77%
Q3 FY24Q/Q Change
Total Assets
4.2B
↑ 4.87%
Total Liabilities
4.2B
↑ 3.99%
FY18Y/Y Change
Operating Cash Flow
-562.6M
↑ 46.98%
Investing Cash Flow
272.9M
↓ 194.0%
Financing Cash Flow
65.5M
↓ 94.18%
FY19Y/Y Change
Operating Cash Flow
-278.4M
↓ 50.51%
Investing Cash Flow
-417.7M
↓ 253.03%
Financing Cash Flow
823.2M
↑ 1157.35%
FY20Y/Y Change
Operating Cash Flow
-615.0M
↑ 120.87%
Investing Cash Flow
-435.5M
↑ 4.27%
Financing Cash Flow
995.0M
↑ 20.87%
FY21Y/Y Change
Operating Cash Flow
-641.7M
↑ 4.35%
Investing Cash Flow
-273.3M
↓ 37.25%
Financing Cash Flow
1.2B
↑ 25.34%
FY22Y/Y Change
Operating Cash Flow
-541.3M
↓ 15.65%
Investing Cash Flow
169.4M
↓ 161.97%
Financing Cash Flow
425.8M
↓ 65.86%
Q2 FY23Q/Q Change
Operating Cash Flow
-59.0M
↓ 64.57%
Investing Cash Flow
-8.7M
↓ 88.57%
Financing Cash Flow
53.4M
↑ 15.15%
Q3 FY23Q/Q Change
Operating Cash Flow
359.4M
↓ 709.32%
Investing Cash Flow
-10.8M
↑ 23.54%
Financing Cash Flow
33.1M
↓ 37.94%

Technicals Summary

Sell

Neutral

Buy

Alnylam Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-16.95%
63.94%
50.31%
30.85%
117.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-21.61%
-24.74%
-7.55%
13.66%
101.19%
Biontech Se
Biontech Se
1.94%
14.27%
14.47%
-63.37%
445.2%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.06%
0.04%
27.74%
141.35%
101.98%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.41
18.41
1.11
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.53
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.8B
117.83%
NA
-15.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.8B
101.19%
18.41
33.61%
Biontech Se
Biontech Se
Buy
$25.9B
445.2%
160.8
-15.36%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.0B
101.98%
32.84
-4.51%

Insights on Alnylam Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 659.82M → 500.91M (in $), with an average decrease of 24.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -16.88M → -111.57M (in $), with an average decrease of 560.6% per quarter

Institutional Holdings

  • Capital World Investors

    12.80%

  • FMR Inc

    11.38%

  • Vanguard Group Inc

    9.80%

  • BlackRock Inc

    7.40%

  • Wellington Management Company LLP

    4.82%

  • Capital Research Global Investors

    4.07%

Corporate Announcements

  • Alnylam Pharmaceuticals, Inc. Earnings

    Alnylam Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Organization
Alnylam Pharmaceuticals, Inc.
Employees
2100
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Industry
Health Technology

FAQs